TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation

~ Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient ~ Patient previously intolerant to oral voriconazole therapy successfully treated with TFF VORI

Daniel Carlson

September 8, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

1 COMMENT

AustinBill September 8, 2022 at 4:15 pm

You need to login to view this content.

Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.